topiramate
topiramate is listed in the FDA National Drug Code directory with 149 NDC codes, marketed under brand names including Topamax, topiramate, TOPIRAMATE. Available dosage forms: tablet, coated, tablet, film coated, powder, capsule, extended release, capsule, coated pellets.
Drug details
- Generic Name
- topiramate
- Brand Names
- Topamax, topiramate, TOPIRAMATE, Trokendi XR
- Application Number
- NDA020505
- Sponsor
- Janssen Pharmaceuticals, Inc.
- NDC Codes
- 149
- Dosage Forms
- TABLET, COATED, TABLET, FILM COATED, POWDER, CAPSULE, EXTENDED RELEASE, CAPSULE, COATED PELLETS
- Routes
- ORAL
- Active Ingredients
- TOPIRAMATE
Indications and Usage
1 INDICATIONS AND USAGE Topiramate is indicated for: • Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ) • Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy Topiramate tablets and topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy Topiramate tablets and topiramate capsules are indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. 1.3 Migraine Topiramate tablets and topiramate capsules are indicated for the preventive treatment of migraine in patients 12 years of age and older.